The CrisBio® platform harnesses pupae from the Trichoplusia ni as living yet immobile bioreactors that can be harnessed in a fully automated system to take recombinant protein production to the next level.
Developed originally for vaccine production. CrisBio® relies on Baculovirus Expression Vector Systems (BEVS).
BEVS are one of the most powerful, robust and versatile eukaryotic expression systems, significantly increasing the speed and versatility of expression of a wide variety of protein families allowing the acceleration of development times of protein-based products.
An automated platform that can produce milligrams up to several grams of recombinant protein little incremental investment, high flexibility and immediate linear scalability
A simple and robust process that has proven efficient in producing complex proteins, peptides and enzymes, which required post-translational modifications
Patented workflow employs pupae from the Trichoplusia ni, the natural host of the baculovirus vector, harnessing efficienciess that have naturally evolved
High expression in insect biomass
Suitable for proteins which require multiple post – translational modifications
Automated process: simple, robust, reproducible
Linear & immediate scalability and flexibility
No mammalian components; high biosafety
No zoonotic risk
Lower COGS and Capex
To get started, simply make a request through the form below for the recombinant protein of interest and our team will reach out to you shortly.